Stockreport

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

Amylyx Pharmaceuticals, Inc.  (AMLX) 
PDF Completion of recruitment for pivotal Phase 3 LUCIDITY trial of avexitide expected in Q1 2026, with topline data anticipated in Q3 2026Cash runway expected into 2028, th [Read more]